Paliperidone or placebo added to ongoing treatment for persistent OCD symptoms
About this title
Read the official source — NCT00632229Researchers compared Paliperidone and placebo to find out how the approaches affected obsessive thoughts and compulsive behaviours in people with OCD.
Understand this study
What did researchers investigate?
Researchers compared Paliperidone and placebo to find out how the approaches affected obsessive thoughts and compulsive behaviours in people with OCD.
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- St. Petersburg and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 34
- Sponsor
- University of South Florida
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00632229
- Official title
Show the full official title
Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
St. Petersburg · Indianapolis
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Paliperidone and placebo to find out how the approaches affected obsessive thoughts and compulsive behaviours in people with OCD.
Who is behind this study?
The study sponsor is University of South Florida, a university.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone and Placebo.
Who was this study for?
Listed age limits: 18 years to 70 years.
